Product Description
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: HIV Infections
Phase 1: HIV Infections|Tuberculosis|Cross Infection|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HER2E-PAM, PAMILIA Study | N/A |
Not yet recruiting |
Intestinal Diseases|Enterocolitis |
2023-03-01 |
|
2008-006049-26 | P2 |
Terminated |
HIV Infections |
2013-07-15 |
|
2010-020860-39 | P2 |
Terminated |
HIV Infections |
2013-04-30 |
|
A5271037 | P2 |
Terminated |
HIV Infections |
2013-04-01 |